Annelies M.C. Mavinkurve-Groothuis

Dr. Annelies M.C. Mavinkurve-Groothuis

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2021 in Cancers
Verified
Journal Article
Open access
PDF file
AGAlissa Groenendijk
Alissa Groenendijk
FSFilippo Spreafico
Filippo Spreafico
Ronald de KrijgerRonald de Krijger
Ronald de Krijger
JDJarno Drost
Jarno Drost
JBJesper Sune Brok
Jesper Sune Brok
AMAnnelies M.C. Mavinkurve-Groothuis
Annelies M.C. Mavinkurve-Groothuis
In high-income countries, the overall survival of children with Wilms tumors (WT) is ~90%. However, overall, 15% of patients experience tumor recurrence. The adverse prognostic factors currently used for risk stratification (advanced stage, high risk histology, and combined loss of heterozygosity at 1p and 16q in chemotherapy-naïve WTs) are present in only one third of these cases, and the significance of these factors is prone to change with advancing knowledge and improved treatment regimens. Therefore, we present a comprehensive, updated overview of the published prognostic variables for WT recurrence, ranging from patient-, tumor- and treatment-related characteristics to geographic and socioeconomic factors. Improved first-line treatment regimens based on clinicopathological characteristics and advancing knowledge on copy number variations unveil the importance of further investigating the significance of biological markers for WT recurrence in international collaborations.

26 July 2023 in Cancers
Verified
Journal Article
Open access
PDF file
FWFrancis Simone, Petronella, Louisa Wens
Francis Simone, Petronella, Louisa Wens
CHCaroline Hulsker
Caroline Hulsker
MFMarta Fiocco
Marta Fiocco
JZJózsef Zsiros
József Zsiros
SSStephanie E. Smetsers
Stephanie E. Smetsers
AMAnnelies M.C. Mavinkurve-Groothuis
Annelies M.C. Mavinkurve-Groothuis
Background: Small-cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare aggressive ovarian malignancy mainly affecting children, adolescents, and young adults. Since the discovery of mutations in the SMARCA4 gene in 2014, SCCOHT has become the subject of extensive investigation. However, international uniform treatment guidelines for SCCOHT are lacking and the outcome remains poor. The aim of this systematic review is to generate an overview of all reported patients with SCCOHT from 1990 onwards, describing the clinical presentation, genetic characteristics, treatment, and outcome. Methods: A systematic search was performed in the databases Embase, Medline, Web of Science, and Cochrane for studies that focus on SCCOHT. Patient characteristics and treatment data were extracted from the included studies. Survival was estimated using Kaplan–Meier’s methodology. To assess the difference between survival, the log-rank test was used. To quantify the effect of the FIGO stage, the Cox proportional hazard regression model was estimated. The chi-squared test was used to study the association between the FIGO stage and the surgical procedures. Results: Sixty-seven studies describing a total of 306 patients were included. The median patient age was 25 years (range 1–60 years). The patients mostly presented with non-specific symptoms such as abdominal pain and sometimes showed hypercalcemia and elevated CA-125. A great diversity in the diagnostic work-up and therapeutic approaches was reported. The chemotherapy regimens were very diverse, all containing a platinum-based (cisplatin or carboplatin) backbone. Survival was strongly associated with the FIGO stage at diagnosis. Conclusions: SCCOHT is a rare and aggressive ovarian cancer, with a poor prognosis, and information on adequate treatment for this cancer is lacking. The testing of mutations in SMARCA4 is crucial for an accurate diagnosis and may lead to new treatment options. Harmonization and international collaboration to obtain high-quality data on diagnostic investigations, treatment, and outcome are warranted to be able to develop international treatment guidelines to improve the survival chances of young women with SCCOHT.

16 September 2019 in European Radiology
Verified
Journal Article
Open access
PDF file
LNLotte W. E. van Nimwegen
Lotte W. E. van Nimwegen
AMAnnelies M.C. Mavinkurve-Groothuis
Annelies M.C. Mavinkurve-Groothuis
RKRonald R. de Krijger
Ronald R. de Krijger
CHCaroline C. C. Hulsker
Caroline C. C. Hulsker
AGAngelique J. Goverde
Angelique J. Goverde
ALAnnemieke S. Littooij
Annemieke S. Littooij
Objectives: The use of magnetic resonance (MR) imaging in differentiation between benign and malignant adnexal masses in children and adolescents might be of great value in the diagnostic workup of sonographically indeterminate masses, since preserving fertility is of particular importance in this population. This systematic review evaluates the diagnostic value of MR imaging in children with an ovarian mass. Methods: The review was made according to the PRISMA Statement. PubMed and EMBASE were systematically searched for studies on the use of MR imaging in differential diagnosis of ovarian masses in both adult women and children from 2008 to 2018. Results: Sixteen paediatric and 18 adult studies were included. In the included studies, MR imaging has shown good diagnostic performance in differentiating between benign and malignant ovarian masses. MR imaging techniques including diffusion-weighted imaging (DWI) and dynamic contrast-enhanced (DCE) imaging seem to further improve the diagnostic performance. Conclusion: The addition of DWI with apparent diffusion coefficient (ADC) values measured in enhancing components of solid lesions and DCE imaging may further increase the good diagnostic performance of MR imaging in the pre-operative differentiation between benign and malignant ovarian masses by increasing specificity. Prospective age-specific studies are needed to confirm the high diagnostic performance of MR imaging in children and adolescents with a sonographically indeterminate ovarian mass. Key Points: • MR imaging, based on several morphological features, is of good diagnostic performance in differentiating between benign and malignant ovarian masses. Sensitivity and specificity varied between 84.8 to 100% and 20.0 to 98.4%, respectively. • MR imaging techniques like diffusion-weighted imaging (DWI) and dynamic contrast-enhanced (DCE) imaging seem to improve the diagnostic performance. • Specific studies in children and adolescents with ovarian masses are required to confirm the suggested increased diagnostic performance of DWI and DCE in this population.

13 November 2020 in Pediatric Radiology
Verified
Journal Article
Open access
PDF file
CJCarlijn L. Janssen
Carlijn L. Janssen
ALAnnemieke S. Littooij
Annemieke S. Littooij
MFMarta Fiocco
Marta Fiocco
JHJosephine C. B. Huige
Josephine C. B. Huige
RKRonald R. de Krijger
Ronald R. de Krijger
AMAnnelies M.C. Mavinkurve-Groothuis
Annelies M.C. Mavinkurve-Groothuis
Background: The diagnostic workup of ovarian tumors in children and adolescents is challenging because preserving fertility, in addition to oncological safety, is of particular importance in this population. Therefore, a thorough preoperative assessment of ovarian tumors is required. Objective: To investigate the diagnostic value of MR imaging in differentiating benign from malignant ovarian tumors in children and adolescents. Materials and methods: We conducted a retrospective study of all children and adolescents age <18 years who underwent MR imaging of ovarian tumors during 2014–2019 at a pediatric specialty center. Two radiologists reviewed all MR imaging. We used pathology reports to define the histological diagnosis. Results: We included 30 girls who underwent MR imaging for an ovarian tumor. Signs indicative for malignancy were tumors with a diameter ≥8 cm, with areas of contrast enhancement, irregular margins, extracapsular tumor growth, and ascites. All benign and malignant ovarian tumors were correctly identified by the radiologists. Conclusion: The diagnostic utility of MR imaging in classifying ovarian tumors in children and adolescents as benign or malignant is promising and might aid in defining the indication for ovarian-sparing versus non-ovarian-sparing surgery. We recommend evaluating these tumors with MR imaging prior to deciding on surgical treatment.

10 January 2023 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
MOMichael V. Ortiz
Michael V. Ortiz
CKChrista Koenig
Christa Koenig
AAAmy E. Armstrong
Amy E. Armstrong
JBJesper Brok
Jesper Brok
BCBeatriz de Camargo
Beatriz de Camargo
FSFilippo Spreafico
Filippo Spreafico

27 October 2017 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
JHJanna A. Hol
Janna A. Hol
MHMarry M. van Den Heuvel‐Eibrink
Marry M. van Den Heuvel‐Eibrink
NGNorbert Graf
Norbert Graf
KPKathy Pritchard‐Jones
Kathy Pritchard‐Jones
JBJesper Brok
Jesper Brok
AMAnnelies M.C. Mavinkurve-Groothuis
Annelies M.C. Mavinkurve-Groothuis